ASH 2018 | E-selectin antagonist uproleselan for R/R AML: efficacy and safety data

Name: E-selectin antagonist uproleselan for R/R AML: efficacy and safety data
Uploaded: 2018-12-02T00:00:00.000Z
Duration: 1 min 15 s
Description: Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy and safety results for the E-selectin antagonist uproleselan, in addition to chemotherapy, for relapsed/refractory acute myeloid leukemia (NCT03616470). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Daniel DeAngelo • 2 Dec 2018

ASH 2018

Acute Myeloid Leukemia Leukemia Uproleselan

Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy and safety results for the E-selectin antagonist uproleselan, in addition to chemotherapy, for relapsed/refractory acute myeloid leukemia (NCT03616470). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.